Pan European distribution agreement with Arthrex

RNS Number : 1208H

Tissue Regenix Group PLC

13 November 2018

 

Tissue Regenix Group plc

Pan European distribution agreement with Arthrex, Inc.

Leeds, 13 November 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces that its subsidiary 'CellRight Technologies', has entered into an agreement, effective immediately, allowing Arthrex, Inc. to distribute its proprietary 'BioRinse' bone portfolio throughout Europe, with the initial focus on the UK. 

This new agreement builds on the existing US relationship signed in March 2018 and is a direct result of   the collaborative work that Arthrex and Tissue Regenix have been undertaking to evaluate additional business opportunities.

Steve Couldwell, CEO, Tissue Regenix Group plc commented: "I am delighted to announce an extension to our collaboration with Arthrex.  Since signing the US distribution agreement in March we have continued to build a strong alliance, identifying areas where we can work together and leverage the expertise of both companies.  This European agreement allows us to exploit not only our ability to import our BioRinse bone portfolio into the UK facility, but also Arthrex' expansive distribution network, another significant milestone towards our vision of building a leading force in regenerative medicine."  

For more Information:

Tissue Regenix Group plc Caitlin Pearson, Head of Communications	Tel: [phone]
Jefferies International Ltd Simon Hardy / Christopher Binks	Tel:  [phone]
FTI Consulting  Brett Pollard / Mo Noonan/ Mary Whittow	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine.  Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK.  The company's patented decellularisation ('dCELL^®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts.  Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies^®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease.  CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

END

 

 

CNTGGGMCGUPRPGP